The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
4-Amino-N-(6-(1-(2-((4-methyl-3-(trifluoromethyl)phenyl)amino)-2-oxoethyl)-1H-pyrazol-4-yl)-1H-indazol-3-yl)benzamide ID: ALA5272444
Max Phase: Preclinical
Molecular Formula: C27H22F3N7O2
Molecular Weight: 533.51
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: Cc1ccc(NC(=O)Cn2cc(-c3ccc4c(NC(=O)c5ccc(N)cc5)n[nH]c4c3)cn2)cc1C(F)(F)F
Standard InChI: InChI=1S/C27H22F3N7O2/c1-15-2-8-20(11-22(15)27(28,29)30)33-24(38)14-37-13-18(12-32-37)17-5-9-21-23(10-17)35-36-25(21)34-26(39)16-3-6-19(31)7-4-16/h2-13H,14,31H2,1H3,(H,33,38)(H2,34,35,36,39)
Standard InChI Key: YNLPHKBRICRKCX-UHFFFAOYSA-N
Molfile:
RDKit 2D
39 43 0 0 0 0 0 0 0 0999 V2000
-2.7676 2.1290 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.0530 2.5413 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.3412 2.1294 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.3412 1.3042 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.0512 0.8924 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.7676 1.3005 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.5555 2.3849 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.5555 1.0445 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.0424 1.7148 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.6238 2.5435 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.5373 3.3668 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.2723 3.5389 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.6864 2.8221 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.1323 2.2068 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.5146 2.8221 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.9287 2.1046 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7570 2.1046 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.5146 1.3874 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.1711 1.3874 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9995 1.3872 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.4116 0.6717 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.9974 -0.0458 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.1732 -0.0473 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7552 0.6670 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.4116 -0.7630 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.7592 -0.7645 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.1732 -1.4819 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1.9309 -0.7645 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
2.3450 -1.4819 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-3.7699 0.2445 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.1842 -0.3411 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.3986 -1.1412 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.3842 -0.1267 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-2.8130 -1.7270 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.0275 -2.5244 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.8278 -2.7389 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.4116 -2.1573 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.2020 -1.3564 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.0420 -3.5389 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
4 3 2 0
5 4 1 0
1 6 1 0
6 5 2 0
1 7 1 0
6 8 1 0
8 9 2 0
9 7 1 0
3 10 1 0
11 10 1 0
11 12 2 0
12 13 1 0
13 14 1 0
14 10 2 0
13 15 1 0
15 16 1 0
16 17 1 0
16 18 2 0
17 19 1 0
20 19 2 0
21 20 1 0
22 21 2 0
23 22 1 0
24 23 2 0
19 24 1 0
22 25 1 0
23 26 1 0
26 27 1 0
26 28 1 0
26 29 1 0
8 30 1 0
30 31 1 0
31 32 1 0
31 33 2 0
34 32 2 0
35 34 1 0
36 35 2 0
37 36 1 0
38 37 2 0
32 38 1 0
36 39 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 533.51Molecular Weight (Monoisotopic): 533.1787AlogP: 5.23#Rotatable Bonds: 6Polar Surface Area: 130.72Molecular Species: NEUTRALHBA: 6HBD: 4#RO5 Violations: 2HBA (Lipinski): 9HBD (Lipinski): 5#RO5 Violations (Lipinski): 2CX Acidic pKa: 11.97CX Basic pKa: 2.85CX LogP: 4.53CX LogD: 4.53Aromatic Rings: 5Heavy Atoms: 39QED Weighted: 0.22Np Likeness Score: -1.84
References 1. Wang XR, Wang S, Mu HX, Xu KY, Wang XT, Shi JT, Cui QH, Zhang LW, Chen SW.. (2022) Discovery of novel VEGFR-2-PROTAC degraders based on the localization of lysine residues via recruiting VHL for the treatment of gastric cancer., 244 [PMID:36242985 ] [10.1016/j.ejmech.2022.114821 ]